Cytomegalovirus Indirect Immunofluorescence Assay
510(k) K935809
Active
Valid until
No expiry
FDA recalls
None foundDocuments
Trust
Unverified
Regulatory status
| Region | Authorization | Number | Date | Status |
|---|---|---|---|---|
| United States | FDA 510(k)SESE | NumberK935809 | Date5 May 1994 | StatusActive |
Recalls
No FDA recalls found in the data synced 5 Oct 2026.
Coverage
- Active
- Expiring
- Withdrawn
- Listed
- Not covered
United States — FDA 510(k) Active
Specification
- 510(k) Number
- FDA Product Code
- GQH
- Device Class
- Class II
- Regulation
- 21 CFR Part 866.3175
- Advisory Committee
- Microbiology
- FDA Decision
- SESE Substantially Equivalent
Overview
AI-generated summary, 1 Oct 2026
This device is an Antigen, Cf (Including Cf Control), Cytomegalovirus assay, classified under product code GQH and device class II. It employs an indirect immunofluorescence technique to detect the lower matrix protein pp65 of human cytomegalovirus (CMV) in cytospin preparations of peripheral blood leukocytes, aiding in the diagnosis of CMV infection. The assay is designed for use in microbiology laboratories to identify CMV antigenemia in clinical samples, supporting patient management in immunocompromised or high-risk populations.
The Cytomegalovirus Indirect Immunofluorescence Assay is supplied as a single-use diagnostic reagent kit, intended for use in sterile laboratory settings by trained personnel. It is regulated under FDA 510(k) clearance (K935809) and falls under Special Controls for microbiology applications. No MRI safety considerations apply, as it is a laboratory reagent. Storage and handling must comply with standard virology assay protocols to maintain assay integrity.
Other devices from Light Diagnostics
Questions
AI-generated answers, 1 Oct 2026
What is the Cytomegalovirus Indirect Immunofluorescence Assay used for?
This assay detects the lower matrix protein pp65 of human cytomegalovirus (CMV) in cytospin preparations of peripheral blood leukocytes. It supports the diagnosis of CMV infection by identifying CMV antigenemia in clinical samples, which is particularly useful for managing patients who are immunocompromised or at high risk for CMV-related complications.
How is the Cytomegalovirus Indirect Immunofluorescence Assay supplied?
The assay is supplied as a single-use diagnostic reagent kit. It is designed for use in sterile laboratory settings by trained personnel, ensuring controlled and consistent testing conditions for accurate results.
Is the Cytomegalovirus Indirect Immunofluorescence Assay sterile?
Yes, the assay is intended for use in sterile laboratory settings. While the kit itself is not explicitly labeled as sterile packaging, its design and intended use require adherence to standard virology assay protocols to maintain sterility and assay integrity during handling and testing.
Can the Cytomegalovirus Indirect Immunofluorescence Assay be reused?
No, the assay is explicitly designed as a single-use diagnostic reagent kit. Reuse is not recommended as it could compromise the accuracy and reliability of the results due to potential contamination or degradation of the reagents.
What regulatory pathway does the Cytomegalovirus Indirect Immunofluorescence Assay follow?
The assay is regulated under the FDA 510(k) clearance pathway, specifically with clearance number K935809. It falls under Special Controls for microbiology applications and is classified under product code GQH as an Antigen, Cf (Including Cf Control), Cytomegalovirus, categorized as a Class II device.